Literature DB >> 11867112

Use of proteomic patterns in serum to identify ovarian cancer.

Emanuel F Petricoin1, Ali M Ardekani, Ben A Hitt, Peter J Levine, Vincent A Fusaro, Seth M Steinberg, Gordon B Mills, Charles Simone, David A Fishman, Elise C Kohn, Lance A Liotta.   

Abstract

BACKGROUND: New technologies for the detection of early-stage ovarian cancer are urgently needed. Pathological changes within an organ might be reflected in proteomic patterns in serum. We developed a bioinformatics tool and used it to identify proteomic patterns in serum that distinguish neoplastic from non-neoplastic disease within the ovary.
METHODS: Proteomic spectra were generated by mass spectroscopy (surface-enhanced laser desorption and ionisation). A preliminary "training" set of spectra derived from analysis of serum from 50 unaffected women and 50 patients with ovarian cancer were analysed by an iterative searching algorithm that identified a proteomic pattern that completely discriminated cancer from non-cancer. The discovered pattern was then used to classify an independent set of 116 masked serum samples: 50 from women with ovarian cancer, and 66 from unaffected women or those with non-malignant disorders.
FINDINGS: The algorithm identified a cluster pattern that, in the training set, completely segregated cancer from non-cancer. The discriminatory pattern correctly identified all 50 ovarian cancer cases in the masked set, including all 18 stage I cases. Of the 66 cases of non-malignant disease, 63 were recognised as not cancer. This result yielded a sensitivity of 100% (95% CI 93--100), specificity of 95% (87--99), and positive predictive value of 94% (84--99).
INTERPRETATION: These findings justify a prospective population-based assessment of proteomic pattern technology as a screening tool for all stages of ovarian cancer in high-risk and general populations.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867112     DOI: 10.1016/S0140-6736(02)07746-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  445 in total

1.  Identification of treatment efficacy-related host factors in chronic hepatitis C by ProteinChip serum analysis.

Authors:  Naoki Fujita; Mamoru Nakanishi; Jun Mukai; Yuuji Naito; Takafumi Ichida; Masahiko Kaito; Toshikazu Yoshikawa; Yoshiyuki Takei
Journal:  Mol Med       Date:  2010-10-05       Impact factor: 6.354

2.  Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.

Authors:  Shengjun Wu; Kai Xu; Guang Chen; Jun Zhang; Zhiwei Liu; Xinyou Xie
Journal:  Int J Clin Oncol       Date:  2011-06-03       Impact factor: 3.402

3.  Opportunities and challenges in omics.

Authors:  Mingming Ning; Eng H Lo
Journal:  Transl Stroke Res       Date:  2010-12-01       Impact factor: 6.829

4.  Microdissection, microarrays and proteomics: a new approach to the study of eye diseases.

Authors:  Vassiliki Poulaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-06-26       Impact factor: 3.117

Review 5.  Clinical applications of proteomics: proteomic pattern diagnostics.

Authors:  Emanuel E Petricoin; Cloud P Paweletz; Lance A Liotta
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-10       Impact factor: 2.673

Review 6.  Host-environment medicine: a primary care model for the age of genomics.

Authors:  Peter M Rabinowitz; Alex Poljak
Journal:  J Gen Intern Med       Date:  2003-03       Impact factor: 5.128

7.  Protein microchips in quantitative assays for tumor markers.

Authors:  E I Dementieva; A Yu Rubina; E L Darii; V I Dyukova; A S Zasedatelev; T V Osipova; T P Ryabykh; A Yu Baryshnikov; A D Mirzabekov
Journal:  Dokl Biochem Biophys       Date:  2004 Mar-Apr       Impact factor: 0.788

8.  Biomarkers for type 1 diabetes.

Authors:  Sharad Purohit; Jin-Xiong She
Journal:  Int J Clin Exp Med       Date:  2008-02-29

9.  Syndromic incidence of ovarian carcinoma after liver transplantation, with special reference to anteceding breast cancer.

Authors:  Ernesto P Molmenti; Hebe Molmenti; Jeffrey Weinstein; Eric E Elliott; Carlos G Fasola; Douglas Orr; Joann Blum; Daniel Savino; W Mark Hamilton; Robert M Goldstein; Marlon F Levy; Goran B Klintmalm
Journal:  Dig Dis Sci       Date:  2003-01       Impact factor: 3.199

Review 10.  Proteomics in cancer screening and management in gynecologic cancer.

Authors:  Wei Hu; Weiguo Wu; Ryuji Kobayashi; John J Kavanagh
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.